本刊首页 > 期刊目次 > 阿立哌唑片与利培酮片治疗自闭症谱系障碍与注意缺陷多动障碍共病患儿的疗效对比

• 文章 •

阿立哌唑片与利培酮片治疗自闭症谱系障碍与注意缺陷多动障碍共病患儿的疗效对比

  • 李丹丹

* 通信作者: 李丹丹, 单位:鹤壁煤业(集团)有限责任公司总医院

摘要

【摘要】
目的:对比阿立哌唑片与利培酮片治疗自闭症谱系障碍与注意缺陷多动障碍共病患儿的效果及其药物安全性分析。

方法:随机将我科2017年1月至2019年7月期间98例自闭症谱系障碍与注意缺陷多动障碍共病患儿进行分组,阿立哌唑组49例给予阿立哌唑片治疗,利培酮片组49例给予利培酮片治疗,连续治疗12周后,在治疗前(T0)、治疗4周末(T1)和12周末(T2)时,采用注意缺陷/多动评定量表( ADHD-RS)对比整体ADHD症状改善效果,采用康纳斯行为多动因子(CRSR-1) 对比多动症改善效果,采用CRSR不注意缺陷-冲动因子(CRSR-H) 对比注意力缺陷改善效果,采用临床整体印象-严重程度量表( CGI-S) 及儿童总体评估量表( C-GAS) 评分对比整体功能改善效果,记录治疗期间患儿不良事件发生情况。

结果:两组治疗方案均可不同程度降低治疗后ADHD-RS评分、CGI-S评分、多动评分、多动-冲动因子评分和提高C-GAS评分,但阿立哌唑组降低ADHD-RS评分、CGI-S评分、多动评分、多动-冲动因子评分和提高C-GAS评分幅度优于利培酮片组(P<0.05);12周治疗期间,两组患者药物不良事件发生情况对比(p>0.05),无可比性。

结论:利培酮片、阿立哌唑均可改善自闭症谱系障碍与注意缺陷多动障碍共病患儿的症状群,促进患儿早期融入社会。

关键词:【关键词】阿立哌唑片;利培酮片;自闭症谱系障碍;注意缺陷多动障碍;不良反应

ABSTRACT

【Abstract】
Objective: To compare the efficacy and drug safety of aripiprazole and risperidone in the treatment of children with autism spectrum disorder and attention deficit hyperactivity disorder.

Methods: Randomly divide 98 cases of children with autism spectrum disorder and attention deficit hyperactivity disorder from January 2017 to July 2019, and 49 patients in the aripiprazole group were treated with aripiprazole tablets 49 cases of risperidone tablets were treated with risperidone tablets. After 12 weeks of continuous treatment, attention deficit/hyperactivity assessment was used before treatment (T0), 4 weekends (T1) and 12 weekends (T2). Table (ADHD-RS) compares the overall ADHD symptom improvement effect, using Connors Behavioral Hyperactivity Factor (CRSR-1) to compare the ADHD improvement effect, uses CRSR inattention deficit-impulse factor (CRSR-H) vs. attention deficit improvement effect The clinical overall impression-severity scale (CGI-S) and child overall assessment scale (C-GAS) scores were used to compare the overall function improvement effect, and the occurrence of adverse events in children during treatment was recorded.

Results: Both treatment regimens can reduce the ADHD-RS score, CGI-S score, hyperactivity score, hyperactivity-impulse factor score and increase C-GAS score after treatment to different degrees, but the aripiprazole group reduced ADHD-RS Score, CGI-S score, hyperactivity score, hyperactivity-impulse factor score and increase C-GAS score are better than risperidone tablets (P<0.05); during 12 weeks of treatment, the incidence of adverse drug events in the two groups of patients Contrast (p>0.05), no comparison.

Conclusion  : Risperidone tablets and aripiprazole can improve the symptom group of children with autism spectrum disorder and attention deficit hyperactivity disorder, and promote their early integration into society.

Key words: [Keywords] aripiprazole tablets; risperidone tablets; autism spectrum disorder; attention deficit hyperactivity disorder; adverse reactions

引用本文 / How to Cite This Article

李丹丹.阿立哌唑片与利培酮片治疗自闭症谱系障碍与注意缺陷多动障碍共病患儿的疗效对比[J]. 国际精神病学杂志, 2021, 48(2): 267-270

参考文献

相关文章